Psychiatry Research
2023
Ricci Valerio, Ceci Franca, Di Carlo Francesco et al.
BACKGROUND Natural Cannabis (NC) and Synthetic Cannabinoids (SCs) use can increase the risk of developing psychotic disorders and exacerbate their course. AIMS To examine the differences between psychoses not associated with cannabis use and those associated with NC and SCs use, evaluating psychotic symptoms, global functioning, dissociative symptoms and suicidal ideation. METHODS The sample of...
Plant-Based Therapeutics, Volume 1
2023
Ivan A. Ross
Brain development is a complex phenomenon from fetal life to adolescence. During this period, the brain’s maturation proceeds through a series of ordered events, including critical periods of plasticity. The brain is particularly sensitive to the environment during the changes. The endocannabinoid system participates directly and indirectly in the plasticity and maturation processes. The main...
Cannabis
2023
Daniel J. Kruger, Karahmet Amila, Sydney M Kaplan et al.
15 citations
Novel cannabinoids require systematic research to inform policies and practices. There is a growing interest in semi-synthetic cannabinoids by consumers, manufacturers, and regulators. However, there is a scarcity of research on these substances. Online discussion forums can provide guidance for research questions when current knowledge is scarce. The current project investigates the topics and...
Integrative Cancer Therapies
2023
Leanna J Standish, Sonia M Malani, Ksenia Lynch et al.
5 citations
In 1991 the U.S. Congress mandated that the National Institutes of Health (NIH) form the Office of Alternative Medicine to study alternative medical therapies, especially in oncology care. Shortly after, the National Cancer Institute (NCI) created its own division of complementary and alternative medicine (Office of Complementary and Alternative Medicine). At the genesis of the field 30 years...
Expert Review of Clinical Pharmacology
2023
Luke J. Ney, Wole Akosile, Chris Davey et al.
8 citations
Preclinical and experimental research have provided promising evidence that medicinal cannabis may be efficacious in the treatment of posttraumatic stress disorder (PTSD). However, implementation of medicinal cannabis into routine clinical therapies may not be straightforward. In this review, we describe some of the clinical, practical, and safety challenges that must be addressed for...
Frontiers in Psychiatry
2023
Angela N Phan, Garth E Terry
6 citations
Cannabis use disorder (CUD) is prevalent in ~2-5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase. No FDA-approved medications for CUD are currently available, despite trials of dozens of re-purposed and novel drugs. Psychedelics have garnered interest as a therapeutic class...